
AADI LLCProfile last edited on: 2/1/2016
16730 Calle De CatalinaPacific Palisades, CA 90272
|
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches and headed by an inventor of ABRAXANE® and the nab® technology platform.. In 2014, the firm achieved an important in-licensing from Celgene AADi's lead product is ABI-009, a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin. The focus is on development of the full potential of the albumin-bound mTOR inhibitor in diseases where the mTOR inhibitors have not or cannot be effectively exploited due to problems of effective drug delivery, safety or effective targeting to the disease site.
AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches and headed by an inventor of ABRAXANE® and the nab® technology platform.. In 2014, the firm achieved an important in-licensing from Celgene AADi's lead product is ABI-009, a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin. The focus is on development of the full potential of the albumin-bound mTOR inhibitor in diseases where the mTOR inhibitors have not or cannot be effectively exploited due to problems of effective drug delivery, safety or effective targeting to the disease site.
|